New award for ezetimibe tablets with marlex pharmaceuticals. Period of performance is april 28, 2024 - april 27, 2025 with four one-year options
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 36E79724D0019
- Awardee
-
Marlex Pharmaceuticals Inc. UEI VSSNJEFMPLB3
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- 6505-- Ezetimibe 10MG Tablets Pre-Solicitation · 36E79724R0004 · Posted Nov 9, 2023
- Last date to order 84% complete
- IDV ceiling
- $14,155,681.05
- Award type
- Single award
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The Department of Veterans Affairs National Acquisition Center awarded a single-award indefinite-delivery contract to Marlex Pharmaceuticals Inc. for ezetimibe 10 mg tablets with a ceiling of $14,155,681.05 on April 28, 2024. The contract carries no set-aside designation.
Work is performed nationwide through established VA and Department of Defense pharmaceutical prime vendor supply chains, serving the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, and Indian Health Service.
The solicitation (36E79724R0004) requested proposals for supply of ezetimibe 10 mg tablets in three bottle configurations: 30-count, 90-count, and 500-count formats to ensure uninterrupted supply across four federal healthcare beneficiary agencies. Annual estimated requirements totaled 29,326 bottles of 30-count tablets, 153,548 bottles of 90-count tablets, and 98,519 bottles of 500-count tablets.
The period of performance runs from April 28, 2024 through April 27, 2025, with four one-year option periods extending the potential completion date to April 27, 2027. The NAICS code is 325412, Pharmaceutical Preparation Manufacturing. Marlex Pharmaceuticals Inc. is a minority-owned, Subcontinent Asian American-owned small disadvantaged business headquartered in New Castle, Delaware.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79724D0019?
36E79724D0019 was awarded to Marlex Pharmaceuticals Inc. by National Acquisition Center (Headquarters) on April 28, 2024.
How much is contract 36E79724D0019 worth?
36E79724D0019's own ceiling is $14,155,681.
Who can order from contract 36E79724D0019?
36E79724D0019 is a single award indefinite delivery contract.
Was contract 36E79724D0019 competed?
The extent of competition for 36E79724D0019 was full and open competition. The government received 3 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV